Predictive and Protective Factors Associated With Colorectal Cancer in Ulcerative Colitis: A Case-Control Study

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 1941-1949

  Velayos, Fernando S ^a   Loftus Jr , Edward V ^b   Jess, Tine ^c   Harmsen, W Scott ^b   Bida, John ^b   Zinsmeister, Alan R ^b   Tremaine, William J ^b   Sandborn, William J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BALSALAZIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CANCER REGISTRY; CHILD; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEADACHE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECTUM POLYP; SMOKING; SPONDYLITIS; SPONDYLOARTHROPATHY; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

EID: 33744551277     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.03.028     Document Type: Article

References (39)

1. Itzkowitz S.H., and Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 287 (2004) G7-G17
2. Ekbom A., Helmick C., Zack M., and Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 (1990) 1228-1233
3. Prior P., Gyde S.N., Macartney J.C., Thompson H., Waterhouse J.A., and Allan R.N. Cancer morbidity in ulcerative colitis. Gut 23 (1982) 490-497
4. Lashner B.A., Heidenreich P.A., Su G.L., Kane S.V., and Hanauer S.B. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 97 (1989) 255-259
5. Nuako K.W., Ahlquist D.A., Mahoney D.W., Schaid D.J., Siems D.M., and Lindor N.M. Familial predisposition for colorectal cancer in chronic ulcerative colitis. a case-control study. Gastroenterology 115 (1998) 1079-1083
6. Eaden J., Abrams K., Ekbom A., Jackson E., and Mayberry J. Colorectal cancer prevention in ulcerative colitis. a case-control study. Aliment Pharmacol Ther 14 (2000) 145-153
7. Askling J., Dickman P.W., Karlen P., Brostrom O., Lapidus A., Lofberg R., and Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120 (2001) 1356-1362
8. Kornfeld D., Ekbom A., and Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 41 (1997) 522-525
9. Shetty K., Rybicki L., Brzezinski A., Carey W.D., and Lashner B.A. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94 (1999) 1643-1649
10. Heuschen U.A., Hinz U., Allemeyer E.H., Stern J., Lucas M., Autschbach F., Herfarth C., and Heuschen G. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 120 (2001) 841-847
11. Greenstein A.J., Sachar D.B., Smith H., Pucillo A., Papatestas A.E., Kreel I., Geller S.A., Janowitz H.D., and Aufses Jr. A.H. Cancer in universal and left-sided ulcerative colitis. factors determining risk. Gastroenterology 77 (1979) 290-294
12. Nuako K.W., Ahlquist D.A., Sandborn W.J., Mahoney D.W., Siems D.M., and Zinsmeister A.R. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis. a case-control study. Cancer 82 (1998) 822-826
13. Loftus Jr. E.V., Sandborn W.J., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Offord K.P., and Melton III L.J. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 110 (1996) 432-440
14. Pinczowski D., Ekbom A., Baron J., Yuen J., and Adami H.O. Risk factors for colorectal cancer in patients with ulcerative colitis. a case-control study. Gastroenterology 107 (1994) 117-120
15. Karlen P., Kornfeld D., Brostrom O., Lofberg R., Persson P.G., and Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 42 (1998) 711-714
16. Bernstein C.N., Shanahan F., and Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 343 (1994) 71-74
17. Bernstein C.N., Blanchard J.F., Metge C., and Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?. Am J Gastroenterol 98 (2003) 2784-2788
18. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., Williams C., Price A., Talbot I., and Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126 (2004) 451-459
19. Bernstein C.N. Challenges in designing a randomized trial of surveillance colonoscopy in IBD. Inflamm Bowel Dis 4 (1998) 132-141
20. Rubin D.T., and Lashner B.A. Will a 5-ASA a day keep the cancer (and dysplasia) away?. Am J Gastroenterol 100 (2005) 1354-1356
21. Moody G.A., Jayanthi V., Probert C.S., Mac Kay H., and Mayberry J.F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis. a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 8 (1996) 1179-1183
22. van Staa T.P., Card T.R., Leufkens H.G., and Logan R.F. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease. a large epidemiological study. Gut 54 (2005) 1573-1578
23. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., Williams C.B., Price A.B., Talbot I.C., and Forbes A. Cancer surveillance in longstanding ulcerative colitis. endoscopic appearances help predict cancer risk. Gut 53 (2004) 1813-1816
24. Kelly J.K., and Gabos S. The pathogenesis of inflammatory polyps. Dis Colon Rectum 30 (1987) 251-254
25. Mpofu C., Watson A.J., and Rhodes J.M. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev (2004) CD000279
26. Rubin C.E., Haggitt R.C., Burmer G.C., Brentnall T.A., Stevens A.C., Levine D.S., Dean P.J., Kimmey M., Perera D.R., and Rabinovitch P.S. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103 (1992) 1611-1620
27. Toruner M., Harewood G.C., Loftus Jr. E.V., Sandborn W.J., Tremaine W.J., Faubion W.A., Schroeder K.W., and Egan L.J. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 428-434
28. Logan R.F., Edmond M., Somerville K.W., and Langman M.J. Smoking and ulcerative colitis. Br Med J (Clin Res Ed) 288 (1984) 751-753
29. Sandborn W.J., Tremaine W.J., Offord K.P., Lawson G.M., Petersen B.T., Batts K.P., Croghan I.T., Dale L.C., Schroeder D.R., and Hurt R.D. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 126 (1997) 364-371
30. Pullan R.D., Rhodes J., Ganesh S., Mani V., Morris J.S., Williams G.T., Newcombe R.G., Russell M.A., Feyerabend C., Thomas G.A., et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 330 (1994) 811-815
31. Allgayer H. Review article. mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl 2 (2003) 10-14
32. Thun M.J., Namboodiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325 (1991) 1593-1596
33. Smalley W., Ray W.A., Daugherty J., and Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. a population-based study. Arch Intern Med 159 (1999) 161-166
34. Bansal P., and Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 91 (1996) 44-48
35. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk. a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
36. Matula S., Croog V., Itzkowitz S., Harpaz N., Bodian C., Hossain S., and Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis. the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 3 (2005) 1015-1021
37. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., and Brentnall T.A. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134 (2001) 89-95
38. Pardi D.S., Loftus Jr. E.V., Kremers W.K., Keach J., and Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124 (2003) 889-893
39. Itzkowitz S.H., and Present D.H. Consensus conference. colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 314-321